Abstract
An assay of high sensitivity and specificity for detection of residual malignant cells in remission bone marrow from patients with acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphoma (NHL) has been developed. The assay combined an immunoselection step with immunoglobulin gene rearrangement analysis by high specific-activity DNA Probes. In experimental conditions, less than one contaminating tumor cell out of 1000 bone marrow cells was detected. A bone marrow contamination was detected in morphologically negative bone marrow specimens from two intermediate-grate non-Hodgkin's lymphoma patients. This method can be of value in determining a true remission status in high-risk ALL and NHL patients.
Original language | English |
---|---|
Pages (from-to) | 473-482 |
Number of pages | 10 |
Journal | Annals of the New York Academy of Sciences |
Volume | 511 |
Publication status | Published - 1987 |
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)